Viral CMV UL146/vCXC1 Biotinylated Antibody
R&D Systems, part of Bio-Techne | Catalog # BAF620
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Specificity
Clonality
Host
Isotype
Applications for Viral CMV UL146/vCXC1 Biotinylated Antibody
Western Blot
Sample: Recombinant Viral CMV UL146/vCXC1 (Catalog # 620-CM)
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: UL146/vCXC1
Cytomegalovirus (CMV), a member of the beta herpesvirus subfamily, typically causes subclinical or latent infections in the normal adult population. However, CMV can cause congenital disease during pregnancy and is a human opportunistic pathogen that affects immunocompromised individuals. The CMV genome has been shown to contain homologs of cellular immunomodulatory proteins, including US28 (a CC chemokine receptor) and a MHC class I homolog. Virulent CMV clinical isolates have also been shown to carry at least 19 genes, designated UL133-UL151, that are not found in laboratory strains that have lost virulence characteristics. Two of these genes, UL146 and UL147, exhibit sequence similarity to CXC chemokines.
The CMV UL146 open-reading frame encodes a 117 amino acid residue precursor protein with a predicted 22 residues signal peptide that is cleaved to generate the mature protein. Recombinant UL146 has been shown to induce calcium mobilization, chemotaxis and degranulation of neutrophils.
Long Name
Alternate Names
Additional UL146/vCXC1 Products
Product Documents for Viral CMV UL146/vCXC1 Biotinylated Antibody
Product Specific Notices for Viral CMV UL146/vCXC1 Biotinylated Antibody
For research use only